Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STS | P08842 | 1/20 | 0.49 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.48 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | HGFAC | Q04756 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.46 |
| ▸ | LCK | P06239 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.45 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | PLAU | P00749 | 2/20 | 0.44 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | PLG | P00747 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2113911 | 0.97 | STS (0.47) | STSHSD11B1PTPN11KDM4EHGFAC | |
| SCHEMBL15912453 | 0.89 | PLAU (0.52) | STSHSD11B1RAB9ACA1CA2 | |
| SCHEMBL1928327 | 0.86 | STS (0.65) | STSKDM4ERAB9ACA1CA2 | |
| SCHEMBL18453430 | 0.85 | HSD11B1 (0.56) | STSHSD11B1KDM4ERAB9ACA1 | |
| SCHEMBL5865527 | 0.85 | STS (0.52) | STSHSD11B1KDM4ERAB9ACA1 | |
| SCHEMBL25314535 | 0.84 | NOTUM (0.45) | STSPTPN11KDM4EHGFACRAB9A | |
| SCHEMBL1050436 | 0.84 | POLB (0.50) | STSRAB9ACA1CA2ALDH1A1 | |
| SCHEMBL30697344 | 0.83 | STS (0.53) | STSPTPN11KDM4EHGFACRAB9A | |
| SCHEMBL14526611 | 0.83 | STS (0.53) | STSPTPN11KDM4EHGFACRAB9A | |
| SCHEMBL6132404 | 0.82 | STS (0.59) | STSRAB9ACA1CA2PLAU |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107108631-B | 6-amino-7-bicyclic-7-deaza-purine derivatives as protein kinase inhibitors | 内尔维阿诺医学科学有限公司 | 2020-06-16 | — | — | CN | disclosed |
| US-10221181-B2 | 6-amino-7-bicyclo-7-deaza-purine derivatives as protein kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2019-03-05 | — | — | US | disclosed |
| US-10221181-B2 | 6-amino-7-bicyclo-7-deaza-purine derivatives as protein kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2019-03-05 | — | — | US | disclosed |
| US-20170327506-A1 | 6-AMINO-7-BICYCLO-7-DEAZA-PURINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | NERVIANO MEICAL SCIENCES S.r.l. (IT) | 2017-11-16 | — | — | US | disclosed |
| US-20170327506-A1 | 6-AMINO-7-BICYCLO-7-DEAZA-PURINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | NERVIANO MEICAL SCIENCES S.r.l. (IT) | 2017-11-16 | — | — | US | disclosed |
| US-20170327506-A1 | 6-AMINO-7-BICYCLO-7-DEAZA-PURINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | NERVIANO MEICAL SCIENCES S.r.l. (IT) | 2017-11-16 | — | — | US | disclosed |
| EP-3218378-A1 | 6-AMINO-7-BICYCLO-7-DEAZA-PURINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | Nerviano Medical Sciences S.r.l. (IT) | 2017-09-20 | — | — | EP | disclosed |
| WO-2016075224-A1 | 6-AMINO-7-BICYCLO-7-DEAZA-PURINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2016-05-19 | — | — | WO | disclosed |
| WO-2016075224-A1 | 6-AMINO-7-BICYCLO-7-DEAZA-PURINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2016-05-19 | — | — | WO | disclosed |
| US-20100105681-A1 | 2,6-QUINOLINYL AND 2,6-NAPHTHYL DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES AS VLA-4 INHIBITORS | LASSOIE MARIE-AGNES | 2010-04-29 | — | — | US | disclosed |
| US-20100105681-A1 | 2,6-QUINOLINYL AND 2,6-NAPHTHYL DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES AS VLA-4 INHIBITORS | LASSOIE MARIE-AGNES | 2010-04-29 | — | — | US | disclosed |
| US-7638630-B2 | Very Late Antigen-4 dependent inflammatory disease; asthma, allergic rhinitis, sinusitis, conjunctivitis, food allergy, inflammatory skin disorders, autoimmune disorders, or atherosclerosis, inflammatory skin disorder; methyl 3-[2-(2,6-dichlorophenyl)-6-quinolinyl]-2-hydroxy-2-propenoate | UCB PHARMA S.A. (BE) | 2009-12-29 | — | — | US | disclosed |
| US-7638630-B2 | Very Late Antigen-4 dependent inflammatory disease; asthma, allergic rhinitis, sinusitis, conjunctivitis, food allergy, inflammatory skin disorders, autoimmune disorders, or atherosclerosis, inflammatory skin disorder; methyl 3-[2-(2,6-dichlorophenyl)-6-quinolinyl]-2-hydroxy-2-propenoate | UCB PHARMA S.A. (BE) | 2009-12-29 | — | — | US | disclosed |
| US-20080064720-A1 | 2,6-Quinolinyl And 2,6-Naphthyl Derivatives, Processes For Preparing Them And Their Uses As Vla-4 Inhibitors | UCB, S.A. (BE) | 2008-03-13 | — | — | US | disclosed |
| US-20080064720-A1 | 2,6-Quinolinyl And 2,6-Naphthyl Derivatives, Processes For Preparing Them And Their Uses As Vla-4 Inhibitors | UCB, S.A. (BE) | 2008-03-13 | — | — | US | disclosed |
| EP-1501801-B1 | 2,6-QUINOLINYL AND 2,6-NAPHTHYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF VLA-4 DEPENDENT DISEASES | UCB PHARMA SA (BE) | 2008-01-23 | — | — | EP | disclosed |
| EP-1870402-A1 | 2,6-quinolinyl and 2,6-naphthyl derivatives, processes for preparing them and their uses as VLA-4 inhibitors | UCB Pharma, S.A. (BE) | 2007-12-26 | — | — | EP | disclosed |
| EP-1501801-A1 | 2,6-QUINOLINYL AND 2,6-NAPHTHYL DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES AS VLA-4 INHIBITORS | UCB, S.A. (BE) | 2005-02-02 | — | — | EP | disclosed |
| WO-2003093237-A1 | 2,6-QUINOLINYL AND 2,6-NAPHTHYL DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES AS VLA-4 INHIBITORS | UCB, S.A. (BE) | 2003-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064720-A1 | 2,6-Quinolinyl And 2,6-Naphthyl Derivatives, Processes For Preparing Them And Their Uses As Vla-4 Inhibitors | VCAM1, HRH4, LTA4H | STS 2660/4885HSD11B1 2544/4885PTPN11 3117/4885 |
| US-20170327506-A1 | 6-AMINO-7-BICYCLO-7-DEAZA-PURINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | DCK, RET, ADK | STS 4548/4885HSD11B1 4544/4885PTPN11 895/4885 |
| US-10221181-B2 | 6-amino-7-bicyclo-7-deaza-purine derivatives as protein kinase inhibitors | DCK, RET, PRKCA | STS 4422/4885HSD11B1 4202/4885PTPN11 939/4885 |
| US-20100105681-A1 | 2,6-QUINOLINYL AND 2,6-NAPHTHYL DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES AS VLA-4 INHIBITORS | SCN4A, NECTIN4, VPS4B | STS 1450/4885HSD11B1 3015/4885PTPN11 3292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.